Advanced search
1 file | 5.55 MB Add to list

The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation

(2020) JOURNAL OF PEDIATRIC UROLOGY. 16(1). p.31.e1-31.e10
Author
Organization
Project
Keywords
Pediatrics, Perinatology, and Child Health, Urology, enuresis, bladderdysfunction

Downloads

  • (...).PDF
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 5.55 MB

Citation

Please use this url to cite or link to this publication:

MLA
Rittig, Sören, et al. “The Pharmacokinetics, Safety, and Tolerability of Mirabegron in Children and Adolescents with Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder and Development of a Population Pharmacokinetic Model–Based Pediatric Dose Estimation.” JOURNAL OF PEDIATRIC UROLOGY, vol. 16, no. 1, 2020, pp. 31.e1-31.e10.
APA
Rittig, S., Baka-Ostrowska, M., Tøndel, C., Vande Walle, J., Kjaeer, B., Passier, P., … Tannenbaum, S. (2020). The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation. JOURNAL OF PEDIATRIC UROLOGY, 16(1), 31.e1-31.e10.
Chicago author-date
Rittig, Sören, Małgorzata Baka-Ostrowska, Camilla Tøndel, Johan Vande Walle, Birgitta Kjaeer, Paul Passier, Brigitte Bosman, Otto Stroosma, and Stacey Tannenbaum. 2020. “The Pharmacokinetics, Safety, and Tolerability of Mirabegron in Children and Adolescents with Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder and Development of a Population Pharmacokinetic Model–Based Pediatric Dose Estimation.” JOURNAL OF PEDIATRIC UROLOGY 16 (1): 31.e1-31.e10.
Chicago author-date (all authors)
Rittig, Sören, Małgorzata Baka-Ostrowska, Camilla Tøndel, Johan Vande Walle, Birgitta Kjaeer, Paul Passier, Brigitte Bosman, Otto Stroosma, and Stacey Tannenbaum. 2020. “The Pharmacokinetics, Safety, and Tolerability of Mirabegron in Children and Adolescents with Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder and Development of a Population Pharmacokinetic Model–Based Pediatric Dose Estimation.” JOURNAL OF PEDIATRIC UROLOGY 16 (1): 31.e1-31.e10.
Vancouver
1.
Rittig S, Baka-Ostrowska M, Tøndel C, Vande Walle J, Kjaeer B, Passier P, et al. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation. JOURNAL OF PEDIATRIC UROLOGY. 2020;16(1):31.e1-31.e10.
IEEE
[1]
S. Rittig et al., “The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation,” JOURNAL OF PEDIATRIC UROLOGY, vol. 16, no. 1, pp. 31.e1-31.e10, 2020.
@article{8658312,
  author       = {Rittig, Sören and Baka-Ostrowska, Małgorzata and Tøndel, Camilla and Vande Walle, Johan and Kjaeer, Birgitta and Passier, Paul and Bosman, Brigitte and Stroosma, Otto and Tannenbaum, Stacey},
  issn         = {1477-5131},
  journal      = {JOURNAL OF PEDIATRIC UROLOGY},
  keywords     = {Pediatrics,Perinatology,and Child Health,Urology,enuresis,bladderdysfunction},
  language     = {eng},
  number       = {1},
  pages        = {31.e1--31.e10},
  title        = {The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation},
  url          = {http://dx.doi.org/10.1016/j.jpurol.2019.10.009},
  volume       = {16},
  year         = {2020},
}

Altmetric
View in Altmetric